KASSEL, Germany, May 28, 2013 /PRNewswire/ -- Biozoom (OTCBB: BIZM), creator of the world's first handheld, non-invasive mobile health monitor for measuring biofeedback in humans revealed appointments to the company's Scientific Advisory Board. The list reads like a who's-who of celebrated scientists. "We are delighted to announce these appointments. As a company dedicated to fully exploring the commercial potential of mobile spectroscopy, these respected scholars, clinicians and inventors are an ideal resource to keep us moving forward," said CEO Hardy Hoheisel.
The Scientific Advisory Board is chaired by Dr. Jurgen Lademann, Director of the Center of Experimental and Applied Cutaneous Physiology (CEACP), at the Department of Dermatology, Venerology and Allergology of Charite Berlin. Charite Berlin is one of the largest hospitals in Europe, and home to more than half of German Nobel Prize winners. Lademann is a leading expert on the non-invasive measurement of biomarkers in human skin. Dr. Lademann and his team validated the accuracy of the Biozoom scanner, correlating its results with those of CEACP's Raman spectrometer. After this validation, the Center used the Biozoom scanner successfully in more than 9 major studies. In addition to his work at CEACP, he is editor of the international journal "Skin Pharmacology and Applied Skin Physiology," and a member of the editorial board of a number of respected journals. Dr. Lademann is joined on the Scientific Advisory Board by three distinguished scientists: Drs. Rudolph W. Kessler, Hasan Mukhtar, and Leonhard Zastrow.
Dr. Kessler is a Professor of Chemistry at Reutlingen University, where he also heads the Process Analysis Group at the Reutlingen Research Institute. Dr. Kessler is very comfortable in the world of technology development, having worked for many years with Mercedes Benz at its Basic Research Department in Stuttgart. Presently, his areas of research and specialization are in optical and spectroscopic process analysis methods in combination with multivariate data analysis. A noted innovator, he was nominated in 2009 for the President of the German Republic's Future Prize, and he won the Research Prize of Reutlingen University in 2009.
Dr. Mukhtar is Professor of Cancer Research and the Director and Vice Chair of the Research Department of Dermatology at the University of Wisconsin Medical Science Center. Dr. Mukhtar specializes in the prevention and treatment of skin disease, including cancer, using dietary agents. The Mukhtar laboratory was the first to establish the potential role of green tea polyphenols for the prevention of skin, lung and prostate cancers. It was also the first to define potential cancer chemopreventive effects of a wide variety of dietary agents. The Mukhtar laboratory has expertise in molecular and cellular biology, biomarker assessment and considerable experience with the use of various animal tumor bioassays of induced and transgenic models. Prof. Mukhtar is member of editorial board and associated editor of 38 scientific magazines and has published more than 500 papers.
Dr. Zastrow serves as a consulting scientist with the Center of Experimental and Applied Cutaneous Physiology at Charite Berlin. He holds 99 patents and has authored more than 100 scientific articles. Prior to his work with CEACP, he spent more than a decade as Senior Vice President of Research and Development for the international cosmetics giant, Coty Inc. Earlier, he was head of the Institute for Fatty Chemistry at the German Academy of Sciences' Central Institute for Organic Chemistry. His areas of research include radiation and the interaction of radiation with biological systems as well as the development of protective and neutralizing systems against free radicals in biological systems.
Dr. Wolfgang Koecher, Biozoom's Chief Technology Officer, comments, "Great breakthroughs attract great minds. The Biozoom Scientifics Advisory Board brings multiple disciplines and perspective together to better explore the many possible ways handheld reflection spectroscopy can benefit consumers, industry and science itself."
Biozoom is an innovative technology development company, specializing in the commercialization of our advances in mobile spectroscopy. Our intellectual property portfolio and ongoing research are positioned to apply Biozoom's technology breakthroughs to a wide range of markets. Our first consumer product, the Biozoom scanner, gives people the feedback they need to manage their health, wellness and fitness on demand. Tested in leading health institutions, our scanner is the first of its kind—a handheld, transdermal device for measuring biomarkers, including antioxidant levels, at the click of a button. Scan results— and customized wellness coaching based on those biomarkers— are sent instantly to a smartphone or online account. The scanner will enable leaders in the health and wellness industry to create new levels of customer loyalty and revenues as a result. For more information, visit www.biozoom.net.
This press release contains "forward-looking statements". Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future, and specifically references to future potential purchase orders and re-orders from consumers and distributors. The reader can identify these forward-looking statements by forward-looking words such as "may," "will," "expect," "potential," "anticipate," "forecast," "believe," "estimate," "project," "plan," "continue" or similar words. The reader should read statements that contain these words carefully because they discuss future expectations, contain projections of future results of operations or of financial condition, or state other forward-looking information. Forward-looking statements include, but are not limited to, statements regarding potential products, customers, revenues, expansion efforts, and future plans and objectives of Biozoom, Inc. ("Biozoom"). The risk factors listed in our disclosure documents and the cautionary language therein provide examples of risks, uncertainties and events that may cause actual results to differ materially from the expectations and projections described by Biozoom in its forward-looking statements. Actual results relating to, among other things, product launch, sales, customer acceptance and market share could differ materially from those currently anticipated in such statements. Factors affecting forward-looking statements include: consumer preferences, competition from more established brands, ability to develop market share; changes in the operating costs; changes in economic conditions, foreign exchange and other financial markets; changes of the interest rates on borrowings; changes in the investments levels; litigation; legislation; environmental, judicial, regulatory, political and competitive developments in areas in which Biozoom operates; technological, mechanical and operational difficulties encountered in connection with Biozoom's development activities; and labor relation matters and costs. The reader should refer to the risk disclosures set out in the periodic reports and other disclosure documents filed by Biozoom from time to time with the Securities and Exchange Commission and other regulatory authorities.